Durham's Chimerix hits 'major milestone' in drug trial enrollment

Durham drug developer Chimerix, Inc. (Nasdaq: CMRX) reached a milestone by hitting full enrollment in a trial to test its lead drug against cytomegalovirus. Trial enrollment isn’t the most important news a drug developer can report, but it is significant because it puts the company back on track to test its experimental drug, called brincidofovir, in the correct patient population. In February, Chimerix disclosed it would take longer than initially anticipated to fully enroll the trial. Specifically,…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news